European Society for Medical Oncology (ESMO) Virtual Congress 2020

19 September 2020 - 21 September 2020

NINJA: Nivolumab does not improve OS vs gemcitabine or PLD in platinum-resistant ovarian cancer

25 Jan 2021 by

Nivolumab does not improve overall survival (OS) in patients with platinum-resistant ovarian cancer when compared with standard second- and subsequent-line chemotherapy, according to the results of the phase III NINJA trial presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

NINJA: Nivolumab does not improve OS vs gemcitabine or PLD in platinum-resistant ovarian cancer

25 Jan 2021

Atezolizumab plus nab-paclitaxel prolongs OS in PD-L1 IC–positive triple-negative breast cancer

21 Oct 2020 by

A combined regimen of atezolizumab and nanoparticle albumin-bound (nab)-paclitaxel (A+nP) improves overall survival (OS) vs placebo plus nab-paclitaxel (P+nP) in patients with previously untreated, inoperable, locally advanced or metastatic, PD-L1 immune cell (IC)–positive triple-negative breast cancer (TNBC), according to the final analysis of the IMpassion130 study.

Atezolizumab plus nab-paclitaxel prolongs OS in PD-L1 IC–positive triple-negative breast cancer

21 Oct 2020

Cemiplimab prolongs survival in advanced NSCLC with high PD-L1 expression

16 Oct 2020 by

First-line cemiplimab significantly improved overall survival (OS) and progression-free survival (PFS) in patients with advanced NSCLC* with PD-L1** tumour expression of ≥50 percent, according to the EMPOWER-Lung 1*** study presented at ESMO 2020.

Cemiplimab prolongs survival in advanced NSCLC with high PD-L1 expression

16 Oct 2020

Surufatinib improves PFS in patients with advanced pNETs

13 Oct 2020 by

Surufatinib, a novel small-molecule inhibitor that targets tumour angiogenesis and immune evasion, improves progression-free survival (PFS) in patients with progressive, advanced, well-differentiated pancreatic neuroendocrine tumours (pNETs), according to results of the SANET-p trial presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Surufatinib improves PFS in patients with advanced pNETs

13 Oct 2020

Osimertinib reduces CNS recurrence in resected EGFR-mutated NSCLC

12 Oct 2020 by

In patients with stage IB–IIIA EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) who have undergone complete tumour resection, adjuvant osimertinib significantly reduces the risk of recurrence, including in the central nervous system (CNS), results of an exploratory analysis of the phase III ADAURA trial have shown.

Osimertinib reduces CNS recurrence in resected EGFR-mutated NSCLC

12 Oct 2020

Individualized starting dose of niraparib effective, well tolerated in Chinese patients with recurrent ovarian cancer

09 Oct 2020 by

Individualized starting dose (ISD) of maintenance niraparib improves progression-free survival (PFS) vs placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), results of the NORA trial have shown.

Individualized starting dose of niraparib effective, well tolerated in Chinese patients with recurrent ovarian cancer

09 Oct 2020

Pembrolizumab + chemo emerging as first-line SoC in advanced oesophageal cancer

05 Oct 2020 by

Pembrolizumab in combination with chemotherapy significantly improves overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) vs chemotherapy alone in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer, according to results of the phase III KEYNOTE-590 study presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Pembrolizumab + chemo emerging as first-line SoC in advanced oesophageal cancer

05 Oct 2020

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma

29 Sep 2020 by

The PD-1 inhibitor nivolumab continues to yield sustained recurrence-free survival (RFS) benefit over ipilimumab with better tolerability at 4 years in the adjuvant setting for patients with resected stage IIIB–C or IV melanoma, according to the CheckMate 238 trial presented at ESMO 2020.

CheckMate 238: Nivolumab still bests ipilimumab at 4 years in advanced melanoma

29 Sep 2020